Paper-COVID - Platform for High-throughput SARS-CoV-2 Screening and Contact Tracing

摘要 目前，对新冠肺炎的大部分诊断检测都是通过对符合条件的人进行当地抽样进行的 出现症状后进行集中实验室检测--在3-4天内返回结果。这是现在补充的 由可以在现场执行相同测试的几个护理点(PoC)系统，更快地返回结果， 但吞吐量要低得多。为了让美国经济的许多要素恢复到更接近正常的功能，比如 作为国际航空旅行，大型雇主，以及以校园为基地的高等学府，将需要我们 从诊断性检测转向大规模、分散和重复的无症状(或前期)筛查 症状)个体。传统的集中式测试的结果时间长度相对较低 现有PoC系统的吞吐量将使这成为一个挑战。 在这里，我们建议开发Paper-COVID-一个结合了临床验证的LAMP检测的模块化平台 (已获得FDA EUA批准)具有基于手机的纸质测试平台，可实现更高的 对无症状的SARS-CoV-2进行吞吐量筛查，并促进自动化接触者追踪。这件事的目标是 努力验证一种新的样品处理技术，将之前开发的LAMP分析移植到一张纸上- 基于格式，构建了三个模块化原型系统，并在来自纽约的临床样本上进行了验证 城市。

Abstract At present, most of the diagnostic testing for COVID-19 has been done through local sampling of those who are symptomatic followed by centralized laboratory testing – returning results in 3-4 days. This is now supplemented by several point-of-care (PoC) systems who can perform the same test on site, returning the result much quicker, but at much lower throughput. To return many elements of the US economy to closer to normal function, such as international air travel, large-scale employers, and campus-based institutes of higher learning, will require us to shift from diagnostic testing to large scale, distributed, and repeated screening of asymptomatic (or pre- symptomatic) individuals. The length of time-to-result for traditional centralized testing and the relatively low throughput of existing PoC systems will make this a challenge. Here we propose to develop Paper-COVID – a modular platform that combines a clinically validated LAMP assay (already with FDA EUA approval) with a mobile phone based paper testing platform that enables much higher throughput screening for asymptomatic SARS-CoV-2 and facilitates automated contact tracing. The goal for this effort is to validate a novel sample processing technique, port the previously developed LAMP assay to a paper- based format, construct three modular prototype systems, and validate it on clinical samples from New York City.